2026 State of Release of Information Technology Report Reveals Market Consolidation, AI Integration, and Escalating Compliance Risks

October 7, 2025 9:00 AM

Black Book Research today announced the release of its landmark study, The 2026 Black Book Report of the State of ROI Technology, available now to healthcare providers, payers, and industry stakeholders. The 36-page report delivers the most comprehensive benchmarking of Release of Information (ROI) technology solutions in the U.S. healthcare market.Access the complimentary report...

Read more

Beyond the Cuts: How Rural Hospitals Are Finding Growth Through Strategic Partnerships

October 7, 2025 9:00 AM

As rural hospitals across the United States grapple with mounting financial pressures, including anticipated Medicaid reductions and the shifting policy landscape brought on by legislation like the "Big Beautiful Bill," many are searching for stability amidst uncertainty. However, some hospitals are doing more than staying afloat, they're growing. The difference? A strategic pivot inward, and the right partner to guide the way.Clarifying...

Read more

CARIN Alliance Announces Nation's First Interoperable Digital Identity Credential Trust Framework Policy, Developed in Partnership with DirectTrust(R) and Kantara Initiative(TM)

October 7, 2025 9:00 AM

The CARIN Alliance recently announced the publication of the nation's first unified digital identity credential trust framework policy, developed in partnership with DirectTrust® and Kantara Initiative™.The CARIN Digital Identity Credential Policy integrates and harmonizes three major trust framework policies:National Institute of Standards and Technology (NIST) 800-53, which governs security and privacy;NIST 800-63, also known as the Digital...

Read more

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

October 7, 2025 8:45 AM

Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025.Dogwood Therapeutics is developing Halneuron®, a highly purified version of tetrodotoxin, to treat...

Read more

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

October 7, 2025 8:30 AM

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).The MoCRA registration expands Sonoma's regulatory footprint, enabling the...

Read more

Momentum Consulting Collaborates With Robert Michel to Help Hospital Laboratories Build Local Services and Revenue

October 7, 2025 8:30 AM

Momentum Consulting today announced a new collaboration with clinical lab industry leader, Robert Michel, to broaden awareness of its consulting services for health systems and hospitals, particularly those wanting to boost the productivity and profitability of their clinical laboratory inhouse testing and outreach programs.Momentum offers a full range of solutions, including profitability optimization, operational effectiveness, regulatory,...

Read more

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

October 7, 2025 8:10 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint, with all once-daily icotrokinra dose groups achieving clinical responsea at Week 12 and...

Read more

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

October 7, 2025 7:30 AM

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced new preclinical results showing that its investigational therapy Telomir-1 reactivated two of the body's most important tumor suppressor genes, MASPIN ("tumor suppressor shield") and RASSF1A ("guardian gene"; also called...

Read more

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

October 7, 2025 7:30 AM

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Family Office Summit in Dubai with the theme of "Unlocking the $1 Trillion Wealth Transfer in Dubai".Panel Discussion Event DetailsDate: October 9, 2025Time: 11:20-11:50 a.m. local...

Read more

Desert Oasis Healthcare Recognizes American Pharmacists Month

October 7, 2025 7:00 AM

Desert Oasis Healthcare (DOHC) is proud to recognize October as American Pharmacists Month, a time to highlight the essential role pharmacists play in keeping our communities healthy.While many people think of pharmacists as the professionals who simply dispense medications, they are also highly trained healthcare providers who do much more. Pharmacists at DOHC work hand-in-hand with doctors, nurses, and other care team members to ensure...

Read more

Las Vegas, Are You Ready for the Hoedown of the Year? 

October 7, 2025 6:00 AM

Get ready to dust off your cowboy boots and grab the whole family for an unforgettable day of fun at the Compassion Center's Coalition for Patient Rights Inaugural Charity Hoedown, happening Saturday, November 15, 2025, from 10 a.m. to 5 p.m. at Paradise Recreation Center. The Hoedown is a celebration for every generation. For just $1 admission, guests can enjoy a day loaded with good old country fun, including:An array of games, including...

Read more

AlzeCure Pharma to Present at Redeye Neurology Day on October 15

October 7, 2025 4:00 AM

AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company will participate at Redeye Neurology Day on October 15 at 11:40 CEST, where CEO Martin Jönsson and CSO Johan Sandin will give a company presentation and answer questions about the latest...

Read more

September Newsletter - Acquisition, Expansion and Growing Potential

October 7, 2025 2:30 AM

iZafe Group (STO:IZAFE-B), September marked the start of an intense autumn where several important developments have significantly strengthened our position. Most notably, the strategic acquisition of Thuisapparatuur Nederland B.V., our Dutch distributor. This means that the entire revenue from existing customers in the Netherlands now accrues directly to iZafe Group, compared to previously when we only received a portion of the license income....

Read more

DEA Marijuana Cruelty Disguised as Process: Will President Trump Stop Delay on Cannabis Medicine For Huntington's and MS Patients

October 6, 2025 1:45 PM

At the center of a growing legal and political firestorm is MMJ BioPharma Cultivation, a pioneering pharmaceutical company that first sought a DEA registration in 2018 to cultivate pharmaceutical-grade cannabis for FDA-approved clinical trials. Despite clear federal law mandating prompt action, the company's application remains stalled - now entering its seventh year of delay. In 2022, Congress passed the Medical Marijuana and Cannabidiol...

Read more

Dubai Marathon Physiotherapy: Your Path to the Finish Line

October 6, 2025 12:15 PM

Participating in a marathon in Dubai requires endurance, but due to the extensive training and physical strain, participants often suffer from overuse injuries and setbacks. That's why marathon physiotherapy becomes your ally not only to aid in your recovery but also to support preventing injuries and enhancing performance. If your marathon preparation plan includes physiotherapy and specific marathon training exercises, you're more likely to...

Read more

Medical Care Technologies (OTC PINK:MDCE) Launches Next-Generation AI Validation Program Targeting Clinical-Grade Accuracy

October 6, 2025 9:30 AM

Medical Care Technologies Inc. (OTC Pink:MDCE) announced its plan to benchmark its upcoming AI diagnostic model against the HAM10000 public dermatology dataset to validate its image recognition architecture for detecting various skin lesion types. The benchmarking process will help evaluate model precision, sensitivity, and specificity relative to peer-reviewed standards. The HAM10000 data will be used under its research license as part of...

Read more

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

October 6, 2025 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided its assessment of the company's Type C Meeting with the U.S. Food and Drug Administration (FDA) on October 2, 2025 to seek their advice for efficient advancement of the company's clinical trial of its novel crofelemer powder formulation for oral solution for the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder....

Read more

Daytona Beach Clinical Trial Site Now Enrolling for Heart Protection Study

October 6, 2025 9:00 AM

Arrow Clinical Trials, a physician-owned clinical research site based in Daytona Beach has announced it is now enrolling participants for a groundbreaking heart protection study. This is a study evaluating the effectiveness of inclisirin, a medication that is already FDA approved for lowering cholesterol, for preventing any major adverse events resulting from clogged arteries, including heart attack, stroke, or gangrene limbs.Eligible candidates...

Read more

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

October 6, 2025 8:30 AM

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on...

Read more

Modular Medical Appoints David Bosshard to Lead its International Expansion for the Pivot Insulin Delivery System

October 6, 2025 8:30 AM

Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabetes market with easy to learn and operate user-friendly, affordable patch pumps, today announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling similar tubeless insulin delivery systems across Europe and...

Read more